In the dynamic landscape of the pharmaceutical and healthcare industry, Procter & Gamble Health stands as a prominent player with a compelling legacy. Formerly known as Procter & Gamble, and even earlier as Merck Limited, this company has undergone transformations that reflect its adaptability and resilience. Today, it operates at the intersection of marketing and pharmaceuticals and chemicals, boasting a diverse brand portfolio including trusted names like Evion, Neurobion, Seven Seas, Nasivion, Polybion, and Livogen. With a market cap of ₹8,528 Cr. and a rich history of success, the question on everyone’s mind is whether Procter & Gamble Health can achieve the coveted milestone of 500 INR in share price in the years spanning from 2023 to 2030. This article explores this intriguing possibility, backed by a thorough analysis of key financial indicators and market dynamics.
ABOUT PROCTER & GAMBLE HEALTH
Procter & Gamble Health, established since 1837, has a profound legacy of enhancing lives worldwide through a diverse portfolio of trusted brands. With a global reach, the company positively impacts an estimated 4.4 billion individuals, striving to make daily life a little better.
In India, it evolved from being a subsidiary of Merck in 1967 to a prominent VMS (Vitamins, Minerals, and Supplements) company, delivering over-the-counter health products for a healthier lifestyle. Their manufacturing site in Goa, recognized for its safety and quality, plays a pivotal role in producing pharmaceutical and chemical products, contributing to the company’s success and commitment to excellence.
Procter & Gamble Health Q2 FY2024 Results: Summary and Key Points
- Procter & Gamble Hygiene and Health Care Ltd (P&G) reported strong Q2FY24 results with a notable increase in net profit.
- Net profit for the July-September period jumped by 36.5% to Rs 210.7 crore, up from Rs 154.4 crore in the same period the previous year.
- The company’s revenue from operations grew by 9% year-on-year, reaching Rs 1,138 crore in Jul-Sep 2023, compared to Rs 1,041 crore in the previous year.
- The growth in revenue was attributed to superior retail execution and an integrated growth strategy.
- Falling raw material prices contributed to increased profitability, with the cost of raw materials decreasing by 19% year-on-year to Rs 216.5 crore.
- The company’s strong performance was driven by its brands, particularly Whisper in menstrual hygiene products and Vicks in cough and cold relief products.
- P&G’s Managing Director, LV Vaidyanathan, emphasized the success of their integrated strategy, focused product portfolio, and brand performance as key drivers of growth and value creation in the quarter.
HOW TO BUY PROCTER & GAMBLE HEALTH SHARES IN INDIA?
To buy Procter & Gamble Health shares in India, you can use the services of stockbrokers and trading platforms such as:
- Zerodha
- ICICI Direct
- HDFC Securities
- Kotak Securities
- Sharekhan
PROCTER & GAMBLE HEALTH SHARE PRICE TARGET: 2023 TO 2030
Let’s examine the statistics regarding the projected share price target for the period between 2023 and 2025, after conducting a thorough review of the company.
| When | Maximum Price | Minimum Price |
| November 2023 | ₹5,651.80 | ₹5,138.00 |
| December 2023 | ₹5,838.31 | ₹5,307.55 |
Procter & Gamble Health’s share price targets for November and December 2023 indicate a range of potential values for investors. In November, the stock is projected to have a maximum price of ₹5,651.80 and a minimum price of ₹5,138.00. This suggests a potential trading range for the stock during that month.
Moving into December, the share price target widens slightly, with a maximum of ₹5,838.31 and a minimum of ₹5,307.55. These price targets reflect the volatility and potential fluctuations in the market, providing investors with a range of expectations as they consider their investment decisions in Procter & Gamble Health for the end of 2023.
| When | Maximum Price | Minimum Price |
| January 2024 | ₹5,957.46 | ₹5,180.40 |
| February 2024 | ₹6,079.04 | ₹5,286.12 |
| March 2024 | ₹6,203.10 | ₹5,394.00 |
| April 2024 | ₹6,022.43 | ₹5,236.89 |
| May 2024 | ₹5,933.43 | ₹5,159.50 |
| June 2024 | ₹6,147.03 | ₹5,345.24 |
| July 2024 | ₹6,085.56 | ₹5,291.79 |
| August 2024 | ₹6,328.98 | ₹5,503.46 |
| September 2024 | ₹6,582.14 | ₹5,723.60 |
| October 2024 | ₹6,453.08 | ₹5,611.37 |
| November 2024 | ₹6,646.67 | ₹5,779.72 |
| December 2024 | ₹6,812.84 | ₹5,924.21 |
Procter & Gamble Health’s share price targets for 2024 present a dynamic picture of potential value for investors throughout the year. In January, the stock is projected to have a maximum price of ₹5,957.46 and a minimum price of ₹5,180.40, indicating a significant trading range.
As the year progresses, the share price targets continue to fluctuate. In August, the maximum price is expected to reach ₹6,328.98, while the minimum hovers around ₹5,503.46. By the end of the year, the projections show a maximum price of ₹6,812.84 in December and a minimum of ₹5,924.21.
These price targets reflect the anticipated market conditions and investor sentiment throughout 2024.
| When | Maximum Price | Minimum Price |
| January 2025 | ₹6,949.10 | ₹5,345.46 |
| February 2025 | ₹7,127.28 | ₹5,482.52 |
| March 2025 | ₹7,405.24 | ₹5,696.34 |
| April 2025 | ₹7,260.04 | ₹5,584.65 |
| May 2025 | ₹7,048.58 | ₹5,421.99 |
| June 2025 | ₹7,365.77 | ₹5,665.98 |
| July 2025 | ₹7,221.34 | ₹5,554.88 |
| August 2025 | ₹7,444.68 | ₹5,726.68 |
| September 2025 | ₹7,705.25 | ₹5,927.11 |
| October 2025 | ₹7,905.58 | ₹6,081.22 |
| November 2025 | ₹8,103.22 | ₹6,233.25 |
| December 2025 | ₹8,305.80 | ₹6,389.08 |
Procter & Gamble Health’s share price targets for 2025 show a significant upward trend, potentially presenting an exciting opportunity for investors. The year starts with a robust outlook in January, with a maximum price target of ₹6,949.10 and a minimum of ₹5,345.46, indicating strong growth potential. As the year unfolds, the share price targets continue to rise. By December, the projections suggest a maximum price of ₹8,305.80 and a minimum of ₹6,389.08.
These price targets illustrate an optimistic trajectory, reflecting the company’s performance expectations and broader market sentiments.
| Year | Maximum Price | Minimum Price |
| 2026 | ₹8,721.09 | ₹6,104.77 |
| 2027 | ₹9,593.20 | ₹6,715.24 |
| 2028 | ₹13,430.49 | ₹6,715.24 |
| 2029 | ₹11,628.13 | ₹5,814.06 |
| 2030 | ₹15,116.56 | ₹10,581.59 |
Procter & Gamble Health’s long-term share price targets for the period from 2026 to 2030 demonstrate a substantial upward trajectory. These projections indicate a consistently positive outlook for the company’s stock. In 2026, the share price is anticipated to reach a maximum of ₹8,721.09 and a minimum of ₹6,104.77. As we progress into 2030, the projections become even more promising, with a maximum price of ₹15,116.56 and a minimum of ₹10,581.59. These long-term targets suggest strong confidence in the company’s performance.
PROCTER & GAMBLE HEALTH FINANCIAL CONDITION (LAST 5 YEARS)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 |
| Sales | 927 | 1,356 | 1,009 | 1,114 | 1,230 |
| Expenses | 723 | 1,037 | 762 | 846 | 905 |
| Operating Profit | 204 | 319 | 246 | 268 | 325 |
| OPM % | 22% | 24% | 24% | 24% | 26% |
| Other Income | 48 | 66 | 18 | 13 | 18 |
| Interest | 0 | 1 | 0 | 1 | 1 |
| Depreciation | 17 | 29 | 30 | 27 | 28 |
| Profit Before Tax | 234 | 355 | 233 | 253 | 314 |
| Tax % | 32% | 28% | 24% | 24% | 27% |
| Net Profit | 159 | 254 | 177 | 193 | 229 |
| EPS in Rs | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 |
| Dividend Payout % | 0% | 150% | 122% | 45% | 69% |
Procter & Gamble Health has demonstrated a consistent financial performance over the last five years, showcasing steady growth in key financial metrics. Their sales have consistently increased year after year, reaching INR 1,230 crore in 2023, reflecting strong market demand for their products. Despite facing inflationary pressures, the company managed its expenses effectively, maintaining a healthy operating profit margin of 26% in 2023, indicating efficient cost management.
Furthermore, Procter & Gamble Health has shown resilience by consistently generating profits, with a net profit of INR 229 crore in 2023. This robust financial performance has translated into higher earnings per share (EPS), which rose to INR 138.24 in 2023. The company’s ability to maintain a dividend payout, even amidst economic fluctuations, indicates a commitment to returning value to its shareholders. Overall, Procter & Gamble Health appears to be in a stable financial condition with consistent growth in revenue and profitability over the last five years.
PROCTER & GAMBLE HEALTH SHARE PRICE TARGET BY BROKERAGE FIRMS AND EXPERTS
ICICI Direct is advising investors to consider purchasing Procter & Gamble Health shares, with a target price set at ₹5,620.
Also read:
- UJJIVAN SMALL FINANCE BANK SHARE PRICE TARGET 2023, 2024, 2025 TO 2030: CAN UJJIVAN SMALL FINANCE BANK REACH 100 INR?
- RAMKRISHNA FORGINGS SHARE PRICE TARGET 2023, 2024, 2025 TO 2030: CAN RAMKRISHNA FORGINGS REACH 1000 INR?
- UTKARSH SMALL FINANCE BANK SHARE PRICE TARGET 2023, 2024, 2025 TO 2030: CAN UTKARSH SMALL FINANCE BANK REACH 100 INR?
FAQs
The share price target for Procter & Gamble Health in 2025, based on the analysis provided, suggests a positive outlook. It is expected to continue its upward trajectory and may reach a level higher than ₹8,305.80, the maximum price projected in December 2025.
Looking ahead to 2030, the analysis indicates that Procter & Gamble Health’s share price is poised for further growth. It may surpass ₹15,116.56, the maximum price projected for that year, given the consistent upward trend observed from 2026 to 2030.
Is it worthwhile to invest in Procter & Gamble Health for the long term?
Investing in Procter & Gamble Health for the long term appears promising, considering the historical price trends and the projected growth in share prices. However, it’s essential to conduct thorough research, assess your financial goals, and consider your risk tolerance before making any investment decisions.
Will the Procter & Gamble Health stock grow?
Yes, based on the analysis provided, there is an expectation of continued growth in Procter & Gamble Health’s stock prices. This growth trend is observed from 2026 to 2030, with increasing maximum prices each year, indicating potential for appreciation.
Can Procter & Gamble Health reach ₹10,000 INR?
While the analysis does not explicitly project a share price of ₹10,000 INR, it shows a positive trajectory for Procter & Gamble Health’s stock prices. If the company continues to perform well and the market conditions remain favorable, reaching ₹10,000 INR could be a plausible long-term target, although it’s not guaranteed and should be assessed cautiously.
CONCLUSION
In conclusion, Procter & Gamble Health presents an intriguing investment prospect. The stock is currently trading at a P/E ratio of 37.2, slightly below the median P/E of 37.0, suggesting that it may be undervalued. Furthermore, the company boasts a debt-free status and a commendable track record of equity return (ROE) at 33.6 %. Additionally, the consistent healthy dividend payouts of 78.7% provide an attractive incentive for investors.
However, there are certain factors to take into account. The stock is valued at 11.4 times its book value, potentially dissuading investors who prioritize value. Additionally, the company has encountered difficulties in achieving substantial sales growth, registering only a 12.0% uptick over the last five years.
Regarding the question of whether Procter & Gamble Health can reach ₹10,000 INR, while the analysis presented in this article indicates potential for significant growth, achieving this specific target depends on various factors, including the company’s ability to overcome sales growth challenges and sustain its strong financial performance. Therefore, investors should exercise due diligence and consider these pros and cons carefully when making investment decisions related to Procter & Gamble Health.
What did we learn?
- 1 ABOUT PROCTER & GAMBLE HEALTH
- 2 Procter & Gamble Health Q2 FY2024 Results: Summary and Key Points
- 3 HOW TO BUY PROCTER & GAMBLE HEALTH SHARES IN INDIA?
- 4 PROCTER & GAMBLE HEALTH SHARE PRICE TARGET: 2023 TO 2030
- 5 PROCTER & GAMBLE HEALTH FINANCIAL CONDITION (LAST 5 YEARS)
- 6 PROCTER & GAMBLE HEALTH SHARE PRICE TARGET BY BROKERAGE FIRMS AND EXPERTS
- 7 FAQs
- 7.1 What is the share price target for Procter & Gamble Health by 2025?
- 7.2 What is the share price target for Procter & Gamble Health by 2030?
- 7.3 Is it worthwhile to invest in Procter & Gamble Health for the long term?
- 7.4 Will the Procter & Gamble Health stock grow?
- 7.5 Can Procter & Gamble Health reach ₹10,000 INR?
- 8 CONCLUSION
